First Wave BioPharma, Inc. (FWBI)
- Previous Close
3.0200 - Open
2.9100 - Bid 2.0900 x 200
- Ask 3.5200 x 200
- Day's Range
2.7200 - 2.9300 - 52 Week Range
2.4200 - 65.0000 - Volume
44,574 - Avg. Volume
102,656 - Market Cap (intraday)
6.116M - Beta (5Y Monthly) 1.21
- PE Ratio (TTM)
-- - EPS (TTM)
-43.2800 - Earnings Date May 12, 2024 - May 16, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
36.00
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; and niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
www.firstwavebio.comRecent News: FWBI
Performance Overview: FWBI
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FWBI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FWBI
Valuation Measures
Market Cap
5.53M
Enterprise Value
2.64M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.53
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.17
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-159.98%
Return on Equity (ttm)
-497.87%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-16.1M
Diluted EPS (ttm)
-43.2800
Balance Sheet and Cash Flow
Total Cash (mrq)
3.71M
Total Debt/Equity (mrq)
22.95%
Levered Free Cash Flow (ttm)
-7.76M